Mehmet Dogan

Mehmet Dogan

Auto-generated profile, based on publicly available information

Mehmet Dogan

Gulhane Military Medical Academy, Haydarpasa Training Hospital Department of Cardiology, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2016 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
MDMehmet Dogan
Mehmet Dogan
OYOmer Yiginer
Omer Yiginer
OUOmer Uz
Omer Uz
UKUgur Kucuk
Ugur Kucuk
GDGokhan Degirmencioglu
Gokhan Degirmencioglu
EDEzgi Davulcu
Ezgi Davulcu

14 February 2018 in Lung
Verified
Journal Article
Closed access
PDF file
MDMehmet Dogan
Mehmet Dogan
TETolga Han Efe
Tolga Han Efe
TCTolga Cimen
Tolga Cimen
COCem Ozisler
Cem Ozisler
MFMehmet Ali Felekoglu
Mehmet Ali Felekoglu
MTMurat Tulmac
Murat Tulmac

1 October 2009 in Clinical & Investigative Medicine
Verified
Journal Article
Open access
PDF file
SMSani N Murat
Sani N Murat
SOSalih Orcan
Salih Orcan
RARamazan Akdemir
Ramazan Akdemir
MDMehmet Dogan
Mehmet Dogan
Emel Mataracı-KaraEmel Mataracı-Kara
Emel Mataracı-Kara
MBMustafa Balci
Mustafa Balci
Objectives: Ivabradine is the first specific heart rate-lowering agent that has completed clinical development for stable angina pectoris. The aim of the present study was to investigate the effects of ivabradine therapy on P-wave duration, dispersion and QT duration, dispersion in coronary artery disease patients. Methods and Results: The study population consisted of 21 patients with CAD who have confirmed by coronary angiography previously. Written informed consent was obtained in all patients. Twelve-lead electrocardiogram was recorded for each subject at a rate of 50mm/s on admission and repeated after 1 month ivabradine therapy. QT duration, QT dispertion, maximum and minimum QT duration calculated. Maximum and minimum P wave and P wave dispersion has been calculated. Heart rate was decreased after ivabradine therapy. (75±15 and 63±10, P=0.02).There was no difference between Pmax, Pmin and Pdis values before and after treatment. QTmax value was prolonged after treatment. (410±43 and 431±14, P=0,005) but there was no difference between cQTmax value.(455±38 and 439±21) There was no difference between QTdis and cQTdis values before and after treatment. (44±18 & 49±14; and 49±22 & 48±15). QTmax was prolonged after ivabradine therapy but cQTmax, Pdis, QTdis and cQTdis were not prolonged. Conclusion: There is no relationship between ivabradine therapy and increased risk of ventricular and atrial arrhythmia in coronary artery disease patient.

1 June 2013 in International Journal of Cardiology
Verified
Journal Article
Closed access
SASadik Acikel
Sadik Acikel
MSMunevver Sari
Munevver Sari
UKUgursay Kiziltepe
Ugursay Kiziltepe
MDMehmet Dogan
Mehmet Dogan
HKHarun Kilic
Harun Kilic
EYEkrem Yeter
Ekrem Yeter

11 July 2016 in Angiology
Verified
Journal Article
Open access
MDMehmet Dogan
Mehmet Dogan
HUHaluk Un
Haluk Un
MAMustafa Aparci
Mustafa Aparci
EKEjder Kardesoglu
Ejder Kardesoglu

1 June 2016
Verified
Closed access
FOF Ozcelik
F Ozcelik
OYO Yiginer
O Yiginer
MDM Dogan
M Dogan
ATA Tokatli
A Tokatli